Personalized Medicine: Immunotherapy Vaccines
Japanese pharma is entering the brave new world of personalized medicine, and the BIO show in Chicago in April brought with it an innovative company that is exploring new cancer treatments. Established three years ago, Green Peptide Co., Ltd. (Fukuoka, Japan) is developing targeted immunotherapies for malignant brain tumors and prostate cancer. Last August and November, the company submitted IND applications for Phase I studies in Japan. Named for the fact that its therapies work naturally, with the body's own processes, Green Peptide's main focus right now is cancer treatment, and providing patients with a better "Quality of life" alternative to chemotherapy or radiation therapy.